Breast Cancer

About Conference

The 6th World Congress on Breast Cancer, scheduled to be held on July 27-28, 2026, in the historic and vibrant city of Rome, Italy, is an internationally acclaimed scientific gathering designed to unite clinicians, researchers, oncologists, surgeons, pathologists, radiologists, pharmaceutical representatives, policy makers, patient advocates, and students from around the world. With a primary focus on innovation, education, and collaboration, this two-day congress is a significant platform dedicated entirely to exploring the most recent advancements, breakthroughs, and challenges in breast cancer research, diagnosis, treatment, and patient care.The 6th edition of this esteemed conference comes at a critical time when global breast cancer incidence continues to rise, making it the most common cancer in women worldwide. According to WHO reports, one in eight women is likely to be diagnosed with breast cancer in her lifetime. Despite increased awareness and progress in early detection and therapy, there are persisting disparities in outcomes due to late diagnosis, limited access to care in low-resource settings, and aggressive subtypes of the disease such as triple-negative breast cancer. 

The conference will encompass a wide array of scientific sessions and keynote addresses delivered by world-renowned experts. The scientific program is designed to cover basic and translational research, clinical trials, surgical and radiation oncology, immunotherapy, targeted therapy, genetics and genomics, liquid biopsies, AI and digital imaging, molecular biology, nursing and patient-centered care, and survivorship issues. Special sessions will be dedicated to HER2-positive and triple-negative breast cancer, metastatic disease, male breast cancer, young women with breast cancer, and breast cancer in low- and middle-income countries. Attendees will gain valuable insights into how personalized medicine and multi-omics approaches are transforming the breast cancer care landscape.A highlight of the congress is the focus on innovative diagnostics and early detection strategies, including artificial intelligence (AI)-driven imaging, liquid biopsies, and risk prediction models, which are revolutionizing how breast cancer is diagnosed at earlier, more treatable stages. 

The selection of Rome, Italy, as the host city offers a unique blend of historical richness, cultural diversity, and scientific excellence. Rome’s legacy of intellectual exploration and its modern infrastructure make it a perfect venue for this prestigious gathering. Delegates will have the chance to experience a scientifically rewarding program while enjoying the charm of the Eternal City—from the Colosseum and Vatican City to authentic Italian cuisine and Mediterranean hospitality.The 6th World Congress on Breast Cancer 2026 is more than just a conference—it is a movement toward a future where breast cancer is no longer a life-threatening disease. 

Sessions and Tracks

• Immunotherapy in Breast Cancer

Immunotherapy has emerged as one of the most transformative approaches in oncology, and its application in breast cancer is opening new avenues for patient care, especially in aggressive and treatment-resistant subtypes. This session will explore the evolving role of immunotherapeutic strategies in breast cancer, including checkpoint inhibitors, cancer vaccines, and adoptive cell therapies. Unlike more immunogenic tumors such as melanoma or non-small cell lung cancer, breast cancer has traditionally been considered immunologically "cold." However, recent studies have shown that certain subtypes, particularly triple-negative breast cancer (TNBC), may respond favorably to immunotherapeutic agents when combined with conventional therapies like chemotherapy. This session will highlight the mechanisms by which breast tumors evade immune surveillance and how new treatments are being designed to counteract these processes. Clinical trial data will be presented to assess the efficacy and safety of these agents in both early-stage and metastatic breast cancer settings. Researchers will discuss factors influencing response rates, such as tumor-infiltrating lymphocytes (TILs), PD-L1 expression levels, and tumor mutational burden. Another area of interest is the development of personalized cancer vaccines aimed at stimulating a robust and sustained immune response against tumor-specific antigens. Attendees will gain insights into the pipeline of neoantigen-based therapies currently under investigation and the technological platforms supporting their production.

• Breast Cancer Survivorship and Quality of Life

As breast cancer survival rates continue to improve due to advances in treatment and multidisciplinary care, a new frontier of care has emerged—long-term survivorship. Breast cancer survivorship is not a singular phase but a dynamic continuum that spans years, often decades, after initial diagnosis and therapy. With survival comes the reality of persistent or late-emerging effects of treatment. The psychosocial aspect of survivorship is another major theme. Many breast cancer survivors experience anxiety, depression, fear of recurrence, and challenges related to body image, sexuality, and identityReturning to work, rebuilding relationships, and managing the expectations of others can create stress and uncertainty. Presenters will discuss strategies to support patients through these transitions, particularly for women who are caregivers themselves or who face cultural stigmas around cancer survivorship. Presentations will cover the impact of physical activity, diet, weight management, and alcohol consumption on survivorship outcomes. Clinical guidelines for healthy living after breast cancer will be shared, along with practical models for integrating lifestyle counseling into follow-up care. The coordination of care between oncologists, primary care providers, rehabilitation specialists, and mental health professionals will be discussed, highlighting the importance of a collaborative approach. For underserved and marginalized populations, survivorship is further complicated by disparities in access to care, socioeconomic stressors, and cultural differences in health beliefs.

• Triple-Negative Breast Cancer Research

Triple-Negative Breast Cancer (TNBC) represents one of the most aggressive and clinically challenging subtypes of breast cancer, accounting for approximately 15–20% of all breast cancer diagnoses. Characterized by the absence of estrogen receptors (ER), progesterone receptors (PR), and HER2 amplification, TNBC does not respond to most endocrine or HER2-targeted therapies, leaving chemotherapy and newer systemic treatments as the main therapeutic approaches. TNBC is highly diverse at the molecular level. Researchers will present updates on intrinsic subtypes such as basal-like, mesenchymal, and luminal androgen receptor (LAR), each with distinct genetic and signaling features. Understanding these subtypes has major implications for prognosis and targeted treatment. The use of PARP inhibitors for patients with BRCA1/2 mutations will also be covered. These agents exploit defects in DNA repair mechanisms to selectively kill cancer cells, offering a more targeted approach for genetically defined TNBC populations. Current strategies combining PARP inhibitors with chemotherapy or immunotherapy will be evaluated, along with discussions on resistance mechanisms and sequencing options. From a clinical management standpoint, experts will address how to optimize treatment sequencing, integrate clinical trial participation, and tailor therapy based on tumor biology. Discussions will also include supportive care strategies and quality-of-life considerations for patients undergoing intensive treatment regimens.

• Immunotherapy and Breast Cancer

Immunotherapy is revolutionizing the landscape of cancer treatment, and its application in breast cancer is rapidly evolving. Although traditionally considered less immunogenic than other tumor types, certain subtypes of breast cancer—most notably triple-negative breast cancer (TNBC)—have shown responsiveness to immune-based therapies. Combination strategies represent a major focus in current research. The synergy between immunotherapy and chemotherapy, targeted therapy, and radiation is under intense investigation. Experts will share insights from recent trials exploring these combinations, aiming to enhance immune system activation while overcoming resistance mechanisms. Checkpoint blockade has emerged as the most promising immunotherapy strategy in breast cancer. Inhibitors targeting programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and CTLA-4 are being actively studied and utilized. Combination strategies represent a major focus in current research. The synergy between immunotherapy and chemotherapy, targeted therapy, and radiation is under intense investigation. Emerging topics will also include the role of the gut microbiome in modulating immune responses and treatment outcomes. Early research suggests that gut flora diversity and composition can influence the efficacy of immunotherapy and may serve as a modifiable factor in patient outcomes.

• HER2-Positive Breast Cancer Advances

HER2-positive breast cancer, defined by the overexpression or amplification of the human epidermal growth factor receptor 2 (HER2), accounts for approximately 15–20% of all breast cancer cases. Once associated with a poor prognosis, HER2-positive breast cancer has become one of the most treatable subtypes due to the development of highly effective targeted therapies. By understanding the molecular underpinnings of HER2-positive disease, participants will gain insight into why this subtype responds so well to targeted therapies. HER2-directed therapies that have transformed patient outcomes. Landmark agents such as trastuzumab and pertuzumab remain the backbone of treatment, especially in early and metastatic settings. Presenters will discuss optimal combinations, duration of therapy, and updates from pivotal trials like CLEOPATRA, APHINITY, and KATHERINE.. These innovative agents combine the precision of monoclonal antibodies with the potency of cytotoxic chemotherapy, offering substantial improvements in progression-free and overall survival. Emerging HER2-targeted therapies will be reviewed, including tyrosine kinase inhibitors (TKIs) like lapatinib, neratinib, and tucatinib. Their role in overcoming central nervous system metastases—a common complication in HER2-positive breast cancer—will be a focus, with trial data supporting their inclusion in systemic treatment strategies. In addition to systemic therapies, the session will examine the integration of HER2-targeted treatments into early-stage disease, including neoadjuvant and adjuvant settings.

• Hormone Receptor-Positive Subtypes

Hormone receptor-positive (HR+) breast cancers represent the most prevalent subtype, accounting for approximately 70% of all breast cancer diagnoses. These tumors express estrogen receptors (ER), progesterone receptors (PR), or both, and are typically characterized by slower growth and a more favorable prognosis compared to other subtypes. However, despite the initial responsiveness to endocrine therapies, recurrence and treatment resistance remain significant challenges. These insights form the basis for tailoring treatment approaches and predicting outcomes.The main focus will be on endocrine therapy, which remains the cornerstone of treatment for HR+ breast cancer. Speakers will examine the use of selective estrogen receptor modulators (SERMs) such as tamoxifen, aromatase inhibitors (AIs), and selective estrogen receptor degraders (SERDs), highlighting indications, efficacy, and adverse effect profiles. Recent updates to guidelines regarding extended adjuvant endocrine therapy duration, especially in high-risk patients, will be presented along with patient selection criteria. The incorporation of CDK4/6 inhibitors—palbociclib, ribociclib, and abemaciclib—into first-line therapy has significantly extended progression-free survival in this setting, and their clinical role will be discussed alongside real-world data and patient case studies. The incorporation of CDK4/6 inhibitors—palbociclib, ribociclib, and abemaciclib—into first-line therapy has significantly extended progression-free survival in this setting, and their clinical role will be discussed alongside real-world data and patient case studies.

•   Breast Cancer Biomarkers and Prognosis

The identification and application of biomarkers have revolutionized the diagnosis, treatment planning, and prognosis of breast cancer. Breast cancer is a highly heterogeneous disease with varying clinical behaviors and treatment responses. Biomarkers serve as measurable indicators of the biological state of a tumor and can be used to classify breast cancer into subtypes, assess aggressiveness, forecast likely clinical outcomes, and predict responsiveness to specific therapies. Beyond these classical markers, attention will turn to proliferation markers such as Ki-67, which provide insights into tumor growth rate and have implications for treatment intensity. Experts will discuss the challenges and variability in Ki-67 assessment, and its evolving utility in distinguishing luminal A from luminal B tumors, and its role in neoadjuvant settings. These tests analyze the expression of multiple genes within a tumor to provide prognostic scores and treatment recommendations. For example, Oncotype DX is frequently used to determine whether a patient with early-stage, HR-positive, HER2-negative breast cancer will benefit from chemotherapy in addition to hormonal therapy. Real-world data, clinical trial outcomes, and guideline updates related to these assays will be reviewed to help clinicians optimize treatment selection.Emerging and investigational biomarkers will also be highlighted. Liquid biopsy technologies, which detect biomarkers non-invasively through blood samples, are especially promising for real-time monitoring and early detection of minimal residual disease or relapse. 

• Radiation Oncology in Breast Cancer

Radiation oncology plays a pivotal role in the multidisciplinary treatment of breast cancer, significantly improving local control and overall survival across various stages of the disease. Hypofractionated whole-breast irradiation (WBI) has been validated through major trials (such as START and FAST-Forward) to be equally effective and safe as conventional fractionation, with added convenience for patients. The session will compare standard and hypofractionated regimens, highlighting patient selection, toxicity profiles, and long-term cosmetic outcomes. The advantages, limitations, and patient eligibility criteria for PBI using techniques such as brachytherapy, external beam radiation, and intraoperative RT will be examined.For locally advanced breast cancer, post-mastectomy radiation therapy (PMRT) remains a critical component of treatment. The session will review evidence supporting PMRT in patients with positive lymph nodes or large tumors, focusing on optimal targeting of chest wall and regional nodes (axillary, supraclavicular, internal mammary). Strategies for minimizing toxicity to nearby organs—such as the heart and lungs—through advanced planning techniques like 3D conformal RT, intensity-modulated radiation therapy (IMRT), and deep inspiration breath-hold (DIBH) will be covered. The evolving use of radiation therapy in metastatic and recurrent settings will also be discussed. 

•   Surgical Innovations in Breast Cancer

Surgery remains a foundational component in the treatment of breast cancer, offering both curative and palliative options. Over the past few decades, significant innovations in surgical techniques have reshaped the landscape of breast cancer care—shifting from radical approaches to more precise, personalized, and aesthetically mindful procedures. Tools such as intraoperative ultrasound, cavity-shave margins, and emerging margin assessment technologies (like optical spectroscopy and micro-CT) will be reviewed for their impact on re-excision rates and local recurrence. Oncoplastic surgery, a transformative approach that combines oncologic resection with plastic surgery techniques, will also be thoroughly discussed. Oncoplastic surgery allows for wider excisions without compromising aesthetic appearance, expanding BCS eligibility for patients with larger tumors or unfavorable tumor-to-breast size ratios. The safety, indications, and contraindications of these techniques will be addressed, especially in the context of tumor location, size, and genetic risk factors. This includes a discussion of outcomes from recent studies validating their oncologic safety when combined with appropriate adjuvant therapy. Axillary surgery is another area of innovation. 
 

•  Neoadjuvant and Adjuvant Therapies

Neoadjuvant and adjuvant therapies have become essential pillars in the comprehensive treatment of breast cancer, significantly improving survival rates and enabling tailored, stage-appropriate care. Neoadjuvant therapy, which involves administering systemic treatments prior to surgery, has gained prominence, especially in patients with triple-negative, HER2-positive, or locally advanced disease. Its primary goals are to reduce tumor size, increase the likelihood of breast-conserving surgery, assess treatment response in vivo, and provide early systemic control. Adjuvant therapy, given after primary surgery, remains a cornerstone in early-stage breast cancer management. It encompasses a range of treatment modalities, including chemotherapy, hormonal therapy, targeted therapy, and radiation therapy, designed to eradicate microscopic residual disease and reduce recurrence risk. Presenters will offer insights into evidence-based treatment algorithms based on tumor subtype, nodal involvement, molecular profiling, and risk assessment tools such as Oncotype DX and MammaPrint. For example, in HER2-positive breast cancer, dual blockade with trastuzumab and pertuzumab in the neoadjuvant setting followed by adjuvant T-DM1 for patients with residual disease has become a standard paradigm. Likewise, for triple-negative breast cancer, the use of immunotherapy in the neoadjuvant setting combined with chemotherapy has shown promising survival benefits

•  Targeted Therapy and Drug Development

Targeted therapy has transformed the landscape of breast cancer treatment by shifting the focus from non-specific cytotoxic agents to precise, molecularly directed interventions. Unlike traditional chemotherapy, targeted therapies are designed to interfere with specific molecular pathways that drive tumor growth and survival. This session will begin by exploring the key molecular targets in breast cancer—such as HER2, CDK4/6, PI3K, and PARP—and the mechanisms through which these targets are manipulated to achieve therapeutic benefit. The success of HER2-directed therapies (trastuzumab, pertuzumab, T-DM1) in altering the course of HER2-positive breast cancer will be discussed as a foundational model of targeted treatment. Clinical trial data supporting their use in both metastatic and early-stage disease will be presented, along with discussions on resistance mechanisms, adverse effect profiles, and ongoing trials aimed at overcoming therapeutic limitations. In triple-negative breast cancer (TNBC)—a subtype historically resistant to most targeted options—recent advances in immunotherapy and the development of antibody-drug conjugates (ADCs) like sacituzumab govitecan have opened new avenues. A rapidly growing class of therapies that deliver cytotoxic agents directly to tumor cells, reducing systemic toxicity. Molecules engineered to simultaneously target two distinct antigens, increasing treatment specificity and reducing escape mechanisms. Designed to penetrate intracellular targets that are otherwise inaccessible to large biologics.

•   Breast Cancer in Men

Though often perceived as a disease affecting only women, breast cancer in men is a rare but important clinical entity that demands greater attention in both research and practice. Accounting for less than 1% of all breast cancer cases, male breast cancer (MBC) presents unique biological, diagnostic, psychological, and therapeutic challenges that distinguish it from its female counterpart. While genetic mutations such as BRCA2 play a significant role, other contributors—including advancing age, radiation exposure, liver disease, estrogen-related conditions (e.g., Klinefelter syndrome), and family history—will be reviewed. Particular emphasis will be placed on the role of hereditary factors and the need for genetic counseling and testing in male patients, especially in the context of familial cancer syndromes. A major challenge in MBC is delayed diagnosis, often due to low public and clinical awareness, as well as social stigma. Unlike women, men are not routinely screened for breast cancer, leading many to present with more advanced disease. From a biological standpoint, MBC is predominantly hormone receptor-positive, with a large proportion of tumors expressing estrogen and progesterone receptors. This profile makes endocrine therapy—particularly tamoxifen—a cornerstone of treatment. Surgical management in men often involves mastectomy due to limited breast tissue, and radiation therapy may be used depending on tumor size, lymph node involvement, and margin status. The use of chemotherapy and HER2-targeted agents, when applicable, will also be reviewed.

• Young Women and Breast Cancer

Health equity and access will be addressed by examining disparities in outcomes across socioeconomic, racial, and geographic lines. Strategies to improve trial enrollment, outreach, and access to novel therapies for underserved populations will be emphasized. Health equity and access will be addressed by examining disparities in outcomes across socioeconomic, racial, and geographic lines. Strategies to improve trial enrollment, outreach, and access to novel therapies for underserved populations will be emphasized. From a biological standpoint, breast cancer in younger women is more likely to present as triple-negative or HER2-positive subtypes, which are typically more aggressive and associated with poorer prognosis. This session will highlight the molecular and clinical characteristics that differentiate tumors in young women from those in older patients, informing decisions about personalized treatment planning. Fertility preservation is one of the most critical concerns for younger breast cancer patients. Chemotherapy and other systemic treatments can impair ovarian function, so the session will delve into oncofertility options such as egg and embryo freezing, ovarian tissue preservation, and the use of GnRH agonists during treatment. Collaboration between oncologists and reproductive endocrinologists will be discussed as essential in maintaining quality of life and future family planning possibilities.

• Metastatic Breast Cancer Management

As breast cancer progresses to more advanced stages, its complexity increases significantly, demanding a multidisciplinary, patient-centered approach. Molecular profiling and liquid biopsy are increasingly essential in guiding individualized treatment decisions. These tools allow clinicians to identify actionable mutations and resistance patterns, enabling tailored therapies that align with tumor biology and patient needs. Central to the discussion will be novel therapeutic agents and combination strategies, including CDK4/6 inhibitors, PI3K inhibitors, PARP inhibitors, and antibody-drug conjugates. These treatments have significantly transformed the standard of care for hormone receptor-positive and HER2-positive disease, extending progression-free and overall survival in many patients. In parallel, immunotherapy and targeted treatments are becoming promising options for selected patient subsets, particularly those with triple-negative subtypes. The integration of immune checkpoint inhibitors and biomarker-driven therapies will be reviewed, along with strategies to overcome immune resistance and optimize patient selection through PD-L1 expression and tumor mutational burden assessments. Health equity and access will be addressed by examining disparities in outcomes across socioeconomic, racial, and geographic lines. 

• Breast Cancer Prevention Strategies

Prevention remains one of the most powerful tools in reducing the global burden of breast cancer. As the incidence of breast cancer continues to rise across both developed and developing nations, the implementation of effective, evidence-based prevention strategies has become a global priority. These include lifestyle elements such as diet, physical activity, alcohol consumption, obesity, reproductive choices, and exposure to environmental carcinogens. Scientific evidence has consistently shown that regular physical activity, a healthy weight, and reduced alcohol intake can significantly lower breast cancer risk. Genetic counseling and risk-reducing strategies are also key components of personalized prevention. Individuals with a strong family history or known mutations in genes like BRCA1, BRCA2, TP53, or PALB2 may benefit from tailored risk-reducing options. The importance of breast self-awareness and clinical vigilance will be highlighted as part of broader early risk identification efforts. While not a substitute for screening, understanding changes in breast tissue and being aware of family history or symptom development plays a critical role in self-initiated healthcare-seeking behavior. Designed for oncologists, primary care providers, gynecologists, public health professionals, genetic counselors, and educators, this session emphasizes that breast cancer prevention is not a single action, but a continuum of strategies. 

•  Psychosocial Aspects of Breast Cancer

Breast cancer affects far more than just the body — it significantly impacts emotional, psychological, social, and spiritual well-being. From the moment of diagnosis, patients often experience a range of intense emotions, including shock, fear, sadness, anxiety, and uncertainty. These psychological reactions can affect treatment decisions, adherence to therapy, and quality of life. One major focus will be the mental health burden associated with breast cancer. Anxiety, depression, and post-traumatic stress symptoms are common among patients and survivors. These changes can lead to a loss of confidence and impact intimate relationships. Social support networks—including family, friends, caregivers, and peer groups—play a vital role in emotional resilience. Different cultural beliefs about illness, stigma, and healing can influence how individuals perceive their disease and access care. Socioeconomic barriers, such as financial toxicity and lack of access to psychosocial services, further compound distress for many patients. Addressing these disparities through community outreach, culturally competent counseling, and financial navigation services will be a key component of the session. special populations, such as adolescents and young adults (AYAs), LGBTQ+ individuals, and patients with recurrent or metastatic disease, who often have unique emotional and social needs. Tailored interventions for these groups will be presented.

• Breast Reconstruction and Cosmetic Surgery

Breast reconstruction and cosmetic surgery play a vital role in the holistic treatment and recovery of breast cancer patients. Beyond the physical restoration of the breast, these procedures contribute significantly to psychological healing, body image, and self-esteem following a mastectomy or lumpectomy. DIEP, TRAM, and latissimus dorsi flaps). Experts will discuss indications, benefits, limitations, and post-operative outcomes of each method, providing attendees with a comprehensive understanding of how to tailor reconstruction plans based on patient needs, tumor characteristics, and treatment timelines. Timing of reconstruction—immediate versus delayed—is another key consideration. While immediate reconstruction is often preferred for its psychological and cosmetic benefits, it must be balanced against potential complications and the need for adjuvant therapies such as radiation. Timing of reconstruction—immediate versus delayed—is another key consideration. While immediate reconstruction is often preferred for its psychological and cosmetic benefits, it must be balanced against potential complications and the need for adjuvant therapies such as radiation.The psychosocial benefits of reconstruction—including improved body image, reduced anxiety, and enhanced sense of wholeness—will be examined alongside the challenges such as surgical complications, dissatisfaction with results, and the need for revision surgeries

• Artificial Intelligence in Breast Imaging

The integration of Artificial Intelligence (AI) into breast imaging represents a transformative advancement in the early diagnosis, risk assessment, and management of breast cancer. As the field continues to evolve, AI technologies are increasingly proving to be invaluable tools for radiologists and clinicians, enhancing accuracy, reducing diagnostic errors, and optimizing workflows. AI, particularly machine learning (ML) and deep learning (DL) algorithms, have shown exceptional capabilities in analyzing mammograms, ultrasound images, and magnetic resonance imaging (MRI) scans with high levels of precision. These tools are now being used to automatically detect abnormalities, such as masses, calcifications, and architectural distortions, which may be early signs of breast cancer. One of the key advantages of AI is its ability to rapidly process vast datasets, enabling more consistent interpretation and supporting radiologists in making timely and informed decisions. These models learn from patterns in medical images to identify suspicious features with increasing sensitivity and specificity. Attendees will learn how AI-assisted mammography is being used not only to flag potentially cancerous lesions but also to reduce false positives and unnecessary biopsies, improving both patient experience and resource efficiency. Beyond detection, AI is making strides in predictive modeling and risk stratification.By integrating imaging data with clinical, genetic, and demographic information, AI systems can estimate a patient’s future risk of developing breast cancer. This has profound implications for personalized screening intervals and preventive strategies.

• Liquid Biopsy and Non-Invasive Diagnostics

Liquid biopsy and other non-invasive diagnostic techniques are revolutionizing the landscape of breast cancer detection, prognosis, and treatment monitoring. Unlike traditional biopsies that require surgical or tissue-based sampling, liquid biopsies analyze circulating biomarkers—such as cell-free DNA (cfDNA), circulating tumor cells (CTCs), and exosomes—from a simple blood sample. Liquid biopsies offer a minimally invasive alternative to tissue biopsies, allowing for frequent sampling over time and providing a dynamic view of tumor evolution. They are particularly useful in cases where tumor tissue is difficult to access or when serial monitoring is required to assess treatment response or detect recurrence. A major highlight will be the role of ctDNA in early cancer detection, prognosis, and treatment monitoring. Studies have demonstrated that specific mutations, methylation patterns, and tumor-specific alterations can be identified in ctDNA with high sensitivity. Although less abundant than ctDNA, CTCs provide unique insights into the biology of metastatic disease and can be cultured or analyzed for gene expression and protein markers, aiding in real-time phenotyping of the tumor. These components show promise as biomarkers for diagnosis, prognosis, and predicting treatment response. Researchers are investigating their utility as part of multi-analyte diagnostic panels for breast cancer subtyping and surveillance. Experts will present ongoing clinical trials and regulatory considerations, alongside discussions about cost-effectiveness, accessibility, and the integration of these tools into standard oncology practice.

• Global Disparities in Breast Cancer Care

Breast cancer remains the most frequently diagnosed cancer among women worldwide, yet the burden of disease and access to care vary significantly across regions. Underlying factors contributing to global disparities, including limited access to screening and diagnostic tools, shortage of trained healthcare professionals, insufficient treatment infrastructure, and sociocultural barriers. In many LMICs, national healthcare budgets are constrained, and cancer care competes with communicable diseases for funding and attention. Additionally, the high cost of therapies, especially newer targeted treatments and biologics, makes them largely inaccessible to vast segments of the global population. Another key area of focus will be the variability in treatment availability. In some regions, patients lack access to even the most basic interventions, such as surgery, radiation therapy, or chemotherapy. This lack of availability severely limits treatment options and directly impacts survival outcomes. Furthermore, pathology and diagnostic services, which are essential for accurate tumor classification and treatment planning, are often under-resourced or absent entirely. Beyond physical resources, educational and cultural factors contribute to disparities. In many societies, stigma surrounding cancer, low health literacy, and misconceptions about treatment result in delayed care-seeking behavior. Women may fear discrimination, social exclusion, or financial ruin if diagnosed, and thus avoid screening or treatment altogether. These include mobile screening units, telemedicine initiatives, training partnerships, and cost-reducing strategies for delivering essential cancer medicines.

• Lifestyle, Nutrition & Breast Cancer Risk

The relationship between lifestyle choices, nutritional habits, and breast cancer risk has gained increasing attention in recent years. As research continues to uncover the biological links between diet, physical activity, body weight, alcohol use, and hormonal regulation, understanding these factors is crucial in both prevention and long-term health management. One of the primary focuses of the session will be the role of obesity and metabolic health in breast cancer risk. Postmenopausal women with obesity are at significantly increased risk due to elevated estrogen levels produced by adipose tissue. One of the primary focuses of the session will be the role of obesity and metabolic health in breast cancer risk. Postmenopausal women with obesity are at significantly increased risk due to elevated estrogen levels produced by adipose tissue. In addition to risk reduction, the role of lifestyle in supporting immune function, hormonal balance, and overall well-being will be explored. Holistic approaches—including mindfulness practices, stress reduction, and sleep hygiene—are increasingly recognized as important aspects of comprehensive cancer care. Integrative strategies combining nutrition, lifestyle, and conventional treatment will be discussed through real-world case studies and clinical guidelines. Regular exercise has been shown to reduce breast cancer risk, decrease recurrence, and alleviate side effects of treatment such as fatigue, lymphedema, and depression. Evidence-based exercise prescriptions tailored for breast cancer patients and survivors will be shared, emphasizing both aerobic and resistance training.

Market Analysis

The global landscape of breast cancer has undergone significant transformation between 2020 and 2030, influenced by shifting demographics, technological innovations, increasing healthcare investments, and rising awareness. Breast cancer remains the most frequently diagnosed cancer among women globally, contributing to approximately 2.3 million new cases in 2020 alone, and the burden is projected to rise steadily through 2030. The evolution of diagnostics, therapeutics, and public health policies has driven substantial changes in both the clinical and commercial domains of breast cancer care. Between 2020 and 2030, breast cancer incidence is expected to rise by 25–30%, primarily due to aging populations, sedentary lifestyles, increasing obesity rates, alcohol consumption, and reproductive health changes.

Regions like Asia-Pacific, Latin America, and parts of Africa are seeing rapid increases in breast cancer cases, fueled by urbanization and lifestyle changes. In contrast, developed regions such as North America and Western Europe are witnessing stable or slightly increasing incidence but with improved survival rates due to early detection and access to advanced therapies.The global breast cancer therapeutics market was valued at approximately USD 20 billion in 2020 and is projected to reach over USD 45 billion by 2030, registering a CAGR of 8–10%.North America continues to dominate the market owing to robust healthcare systems, strong reimbursement policies, and a high prevalence of breast cancer. However, Asia-Pacific is emerging as the fastest-growing market due to rising health expenditure, improving diagnostic access, and large patient populations in countries like China and India. Looking ahead, the global focus is shifting toward personalized, patient-centric, and value-based breast cancer care. Innovations such as genome editing, mRNA vaccines, AI-driven decision support, and wearable health tech are expected to revolutionize prevention, diagnosis, and treatment.

The market will also see a shift toward biosimilars, improving drug affordability and access. From 2020 to 2030, the global breast cancer market has grown rapidly, shaped by innovation, awareness, and policy initiatives. However, significant work remains to ensure that this progress is inclusive and sustainable. The 6th World Congress on Breast Cancer aims to serve as a platform to exchange insights, present research, and collaborate on global solutions to reduce the burden of breast cancer and improve patient outcomes worldwide.

Group Discount

Unlock Exclusive Savings with Our Group Discount!

Join us for the 6th World Congress on Breast Cancer and take advantage of our special group registration offer designed exclusively for teams and institutions.

Offer Highlights:

• 30% Discount on the total registration fee
• Eligibility: Groups of 5 or more participants
• Early Bird Deadline: Valid until October 28, 2025

Whether you're part of an academic institution, clinical practice, research organization, or advocacy group, this is your opportunity to attend at a reduced rate and engage in cutting-edge discussions shaping the future of breast cancer research and treatment.

Participate in inspiring sessions, connect with global experts, and showcase your expertise in Rome—the historic hub of science and innovation!

Register your group today or learn more on the official Breast Cancer 2026 website.

Email: cancer@speakersconclave.com

Call: +44 330 818 7501

Collaborate, Innovate, and Elevate—Together in Rome!

CME Credits

CME Credits – Continuing Medical Education

Continuing Medical Education (CME) plays a critical role in the ongoing development of medical professionals, ensuring that they remain current with the latest innovations, clinical practices, and technologies. Conference Series is proud to organize CME-accredited conferences recognized by the Accreditation Council for Continuing Medical Education (ACCME).

Why Attend for CME Credits?

• Maintain and renew your medical license
• Stay up-to-date with emerging treatments and technologies
• Enhance clinical practice and patient care
• Gain recognition and distinction through speaking opportunities
• Network with global medical experts and thought leaders

CE Credits – Continuing Education

Continuing Education (CE) credits are essential for professionals seeking to maintain and improve their qualifications across diverse fields including healthcare, research, and clinical practice. CE-accredited sessions at this conference provide hands-on learning and industry insights.

Benefits of CE Credits:

• Strengthen your career path and job prospects
• Stay informed with the latest research and innovations
• Fulfill licensing and certification requirements
• Network with professionals and recruiters in your field
• Ideal for medical and clinical researchers, educators, and practitioners

CPD Credits – Continuing Professional Development

CPD (Continuing Professional Development) represents a structured approach to learning that helps professionals enhance their knowledge, skills, and personal qualities throughout their careers. This conference offers CPD-certified content aligned with international educational standards.

Advantages of CPD Accreditation:

• Demonstrate commitment to personal and professional growth
• Enhance employability and career progression
• Fill skill gaps and improve efficiency
• Boost confidence and professional credibility
• Earn CPD hours through education, research, leadership, and more

Important Note:

We are pleased to inform you that participants of the 6th World Congress on Breast Cancer will be eligible to earn CME/CPD credits. The number of credits will be announced closer to the conference date and will be based on active participation and session attendance.

Past Conference Report

Breast Cancer 2025

The 5th World Congress on Breast Cancer, held from July 14-15, 2025 Berlin, Germany, was a tremendous success. The event brought together distinguished oncologists, researchers, clinicians, surgeons, and industry leaders from across the globe, making the gathering truly impactful and memorable.

Key Highlights of the Conference

Global Participation
we were honored to welcome participants from diverse backgrounds and countries, enabling rich cross-cultural knowledge sharing and collaboration.

Eminent Speakers & Experts
The program featured leading oncologists, oncology nurses, surgeons, and researchers who shared their insights through keynote sessions, panel discussions, and oral presentations—sparking meaningful dialogue and partnerships.

Exploring Novel Research
Sessions focused on groundbreaking developments in breast cancer detection, prevention, treatment innovations, survivorship, and patient-centered care, providing attendees with fresh perspectives and clinical updates.

Engaging & Interactive Sessions
the congress included workshops, symposia, poster sessions, live case discussions, and networking activities—keeping participants actively engaged throughout.

Acknowledgments

Our sincere gratitude to the Organizing Committee Members, keynote speakers, panelists, delegates, and sponsors. Your dedication and contributions played a crucial role in the resounding success of Breast Cancer 2025.

Looking Ahead: Breast Cancer 2026

Building on the success of 2025, we are delighted to announce:

6th World Congress on Breast Cancer
July 27–28, 2026
Rome, Italy

Join us for another inspiring and knowledge-rich gathering where science, research, and patient care meet. The 2026 edition promises broader themes, deeper global outreach, and enhanced networking opportunities.

Save the Date!

Let’s reunite in Rome to explore the future of breast cancer research, treatment innovations, and global collaborations. Don’t miss the opportunity to be part of Breast Cancer 2026—a hub for oncologists, researchers, clinicians, advocacy groups, and innovators.

For More Information
Contact: cancer@speakersconclave.com

Call: +44 330 818 7501

With gratitude,
Organizing Committee
Breast Cancer 2026